January 31, 2015 7:48 PM ET


Company Overview of HemoShear, LLC

Company Overview

HemoShear, LLC, a biotechnology research company, develops and creates human-relevant systems that replicate the biology of organ systems and diseases in drug discovery and development. It conducts various experimental programs using human or animal primary cells; recreates in vivo hemodynamic conditions; cultures multiple cell types together to restore native biology; uses primary cells in physiologically accurate media conditions; creates physiologically relevant systems for understanding human responses in healthy and disease states; and provides human vascular systems, including artery systems, arteriole and microvascular systems, advanced inflammatory systems, atherosclerosis-prone cond...

1115 5th Street SW

Charlottesville, VA 22902

United States

Founded in 2008





Key Executives for HemoShear, LLC

Chairman and Chief Executive Officer
Age: 62
Vice Chairman
Vice President of Operations
Compensation as of Fiscal Year 2014.

HemoShear, LLC Key Developments

HemoShear Completes First Phase of Development of Novel Cancer Drug Discovery Platform

HemoShear announced that it has completed the first phase of development of a novel cancer drug discovery platform that replicates human tumor biology and responds to clinically-relevant drug concentrations. Funded by a contract with the NCI, HemoShear is developing a series of tumor models that recreate a wide variety of cancers for discovery of new drugs. Using their new platform, HemoShear was able to successfully replicate human therapeutic response to Cisplatin, a drug approved to treat non-small cell lung carcinomoa, at a therapeutically-relevant concentration. Similarly, HemoShear evaluated two other drugs currently in clinical studies and confirmed a therapeutic response. When evaluated in traditional cell culture systems and mouse studies, the same dose of Cisplatin does not show a response. HemoShear's findings reinforce the need to test cancer drug candidates under more human-relevant tumor conditions. HemoShear's translational tissue systems apply physiological blood flow characteristics to human tissue to restore its in vivo biology, using material from HemoShear's biorepository and interpreting data with cutting edge computational analytics. In phase I of the NCI-funded program, HemoShear demonstrated that NSCLC tumor structure, biology, and molecular signaling pathways are restored in the HemoShear platform.

HemoShear, LLC Presents at BIO International Convention, Jun-23-2014 through Jun-26-2014

HemoShear, LLC Presents at BIO International Convention, Jun-23-2014 through Jun-26-2014. Venue: San Diego Convention Center, San Diego, California, United States. Presentation Date & Speakers: Jun-24-2014, Vincent Aurentz, Chief Business Officer. Jun-25-2014, Brian R. Wamhoff, Co-Founder, Vice President of Research & Development and Director.

HemoShear, LLC Enters into R&D Collaboration with Medivir AB

HemoShear, LLC announced research collaboration with Medivir AB. The collaboration will explore the application of HemoShear's platform in an undisclosed area of strategic interest. In this initial phase of the collaboration, HemoShear will characterize biological mechanisms and the effects of drug candidates on liver tissue using the Company's first-in-class human liver system. The HemoShear human liver system accurately replicates in vivo physiological conditions, enabling a more precise and definitive assessment of targets and drug candidates, drug-induced changes in biology and pharmacological responses. The collaboration with Medivir will also leverage and contribute to the set of drug exposure data HemoShear is creating as part of an ongoing program funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), a division of NIH.

Similar Private Companies By Industry

Company Name Region
Intrexon Energy Partners, LLC United States
MaxCyte, Inc. United States
NanoDetection Technology Inc. United States
AnosiaVax, Inc. United States
OnCore Biopharma, Inc. United States

Recent Private Companies Transactions

Private Placement
May 7, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HemoShear, LLC, please visit www.hemoshear.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.